Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial : vimarsana.com

Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

China , Beijing , Guangzhou , Guangdong , Shanghai , Boston , Massachusetts , United States , Suzhou , Jiangsu , Hangzhou , Zhejiang , Paul Beresford , Caroline Germa , Los Angeles , Product Development Center , Clinical Development Centers , Transcenta Holding , Transcenta Immune Tolerance Breaking Technology , Global Medicine Development , Prnewswire Transcenta Holding Limited , Translational Research Center , Group Headquarters , Agilent Technologies , Holding Limited , Investigational Use , Performance Evaluation Only , Executive Vice President , Chief Medical , Immune Tolerance Breaking Technology , Orphan Drug Designation , Manufacturing Facility , External Partnering Center , Suzhou Industrial ,